Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?

How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?

Moderna is on is way to save the world. But MRNA stock has some resistance above, so the bulls will need to bet busy.

Why Moderna Stock Faces a Tough Slog Ahead

Moderna Inc. said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.

Moderna on track to deliver 200 million doses of its COVID vaccine to U.S. govt by end-June

The stock price of Moderna Inc (NASDAQ: MRNA) has increased by 12.2% as it went from a previous close of $131.02 to $147 on January 25. This is why it happened.

MRNA Stock Price Increased By 12.2%: Why It Happened

A weaker response to the South African variant prompts studies of a strain-specific booster.

Moderna Says Vaccine Protects Against All Known Variants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to host conference call on COVID-19 variants announcement on Monday, Jan. 25 at 4:30 pm ET.

Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25

Shares of Moderna gained as much as 12% Monday following a report from the biotechnology company that its vaccine can likely protect against new mutant strains of the coronavirus. Moderna reached an intraday high of $147.43 soon after the Monday opening bell before paring some gains.  In a press release, Moderna stated that its mRNA-1273 COVID-19 vaccine can probably protect people against variants of the disease first found in South Africa and the UK. The current vaccine showed lower levels of antibodies in lab testing against the South African variant, however. "Out of an abundance of caution," the biotech company will begin testing a booster shot tailored to protect people against the South African variant, according to Moderna CEO Stéphane Bancel.

Moderna climbs 12% after saying its coronavirus vaccine likely protects against new strains found in the UK and South Africa

Moderna stock is trading at 16 times forward price-to-earnings, quite an unrealistic multiple, considering the vaccine race is tightening. The post Vaccine Race Is Catching up to Moderna Stock but Outlook Is Solid appeared first on InvestorPlace.

Vaccine Race Is Catching up to Moderna Stock but Outlook Is Solid

The company is the first developer of a Covid-19 vaccine to announce a program to update its vaccine to protect against one of the newly-identified strains.

Moderna Making Booster to Protect Against South African Covid-19 Strain

Moderna's vaccine works well against the more transmissible U.K. strain but the neutralizing antibody response was found to be lower against the newly discovered South African variant.

Moderna Launches Trial For Covid-19 Vaccine Booster To Tackle South African Strain

The biotech stock has plenty of risks, but it also offers the potential for big rewards.

Is Moderna a Smart Pick for Long-Term Investors?

Moderna has detailed some of the steps it's taking to ensure that its vaccine remains effective in the face of emerging strains of the SARS-CoV-2 virus that leads to COVID-19. These include testing how adding a second booster, for a total of three shots, works with its existing COVID-19 vaccine, and also developing a strain-specific […]

Moderna says it's making variant-specific COVID-19 vaccines, but its existing vaccine should still work

Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. The study was not conducted in humans.

Moderna: Lab study confirms its COVID-19 vaccine still protects against new variants

Moderna's coronavirus vaccine is likely still protective against a viral strain first found in South Africa, but the Massachusetts biotech said Monday it plans to soon start testing a booster shot tailored to protect people against that variant.  Moderna's two-dose COVID-19 vaccine won US authorization in December and has since been rolled out to millions of people. A large-scale studya last year found the shot was overwhelmingly protective against COVID-19, being about 94% effective at preventing symptomatic disease.

Moderna is working on a new version of its COVID-19 shot designed to fight the South African variant

Moderna said it's accelerating work on a Covid-19 booster shot to guard against the recently discovered variant in South Africa.

Moderna says it's working on Covid booster shot for variant in South Africa, says current vaccine provides some protection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna COVID-19 Vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa.

Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

The Centers for Disease Control and Prevention said Friday that Moderna Inc.'s COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency's findings about the coronavirus vaccine developed by BioNTech SE and Pfizer Inc. . Moderna's stock was up 1.6% in premarket trading on Monday.

CDC: Moderna's COVID-19 vaccine can cause allergic reaction in some people

Indian conglomerate Tata Sons are in discussion with Moderna Inc (NASDAQ: MRNA) for a partnership with its healthcare unit Tata Medical & Diagnostics, the Economic Times reported on Monday. What Happened: Tata Medical & Diagnostics could team up with the Indian government's key R&D organization, the Council of Scientific & Industrial Research, to launch and carry out clinical trials for Moderna's COVID-19 vaccine candidate in India, Economic Times reported citing sources familiar with the matter.

Tata In Partnership Talks With Moderna To Launch COVID-19 Vaccine In India: Report

COVID Vaccine Stocks: How Strong Is Moderna's Financial Position?

What Are Moderna's Risks?

The success of Moderna's COVID-19 vaccine could be just the beginning.

Could Moderna Be a Millionaire-Maker Stock?

AstraZeneca

Bank of America

BioNTech SE

Johnson & Johnson

Pfizer

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.

CDC quietly changes Covid vaccine guidance to OK mixing Pfizer and Moderna shots in 'exceptional situations'

Only 0.03% of Moderna shots administered through Jan. 10 resulted in a reported “adverse event.”

Moderna Covid-19 Vaccine Study: Allergic Reactions ‘Rare' With 2.5 Per Million Causing Anaphylaxis

Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.

News for Moderna Stock (MRNA)